CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Novo Nordisk A/S is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Novo Nordisk A/S
Novo Alle 1
Phone: +45 44448888p:+45 44448888 BAGSVAERD, 2880  Denmark Ticker: NOVO BNOVO B

This is a Subsidiary, click here for the Parent Company

Business Summary
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
(Source: 20-F)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes-YesYes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board HelgeLund 61 3/22/2018 3/20/2014
President, Chief Executive Officer LarsFruergaard Joergensen 57 1/1/2017 1/31/2013
Vice Chairman of the Board HenrikPoulsen 56 3/23/2023 3/25/2021
12 additional Officers and Directors records available in full report.

Business Names
Business Name
0QIU
Aldaph SpA
Beijing Novo Nordisk Pharmaceuticals Science & Technology Co., Ltd.
78 additional Business Names available in full report.

General Information
Number of Employees: 63,370 (As of 12/31/2023)
Outstanding Shares: 4,458,300,000 (As of 12/31/2023)
Shareholders: 23,000
Stock Exchange: CPH
Federal Tax Id: 562009773
Fax Number: +45 44436633


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, March 18, 2024